文献速递淋巴瘤白血病

莫塞妥莫单抗帕苏多毒素清除毛细胞白血病微小残留病:1期结果与长期随访

Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up.
PubMed 文献 · Blood · 2018-02-27

在复发/难治性毛细胞白血病(HCL)中,抗CD22免疫毒素莫塞妥莫单抗帕苏多毒素的1期扩展队列联合既往高剂量患者共33例,达64%完全缓解(CR)和88%总缓解率,中位CR持续42.4个月;骨髓流式微小残留病(MRD)阳性CR的中位CR持续时间短于MRD阴性CR(13.5个月 vs 42.1个月,P<.001)。

要点

  • 33例联合队列达64% CR、88% ORR,中位CR持续42.4个月,143个周期无剂量限制性毒性。
  • 32例50µg/kg可评估患者中,MRD阳性CR中位CR持续13.5个月 vs MRD阴性42.1个月(P<.001)。
  • 研究结束时11例MRD阴性CR中10例CR持续、9例仍MRD阴性。

核心结论

  • 莫塞妥莫单抗帕苏多毒素是唯一能在相当比例HCL患者中清除MRD以延长CR持续时间的非化疗方案。
  • 重复给药虽早期出现中和抗体,但增加活性药物水平且未检出免疫原性相关毒性。
  • 其活性与安全性支持正在进行的HCL 3期试验。

研究设计与样本

  • 1期试验扩展队列:21例接受50 µg/kg隔日1次、每周期3次、4周为一周期。
  • 联合既往在该上限剂量水平报告的12例,共33例进行分析。
  • MRD评估采用骨髓穿刺流式细胞术(最严格评估),32例50 µg/kg患者可评估。

主要发现

  • 33例联合队列达64% CR和88%总缓解率,中位CR持续时间42.4个月。
  • 143个周期未出现剂量限制性毒性。
  • 9例MRD阳性CR的中位CR持续13.5(4.9-42.4)个月 vs 11例MRD阴性CR的42.1(24.0-69.2)个月(P < .001)。
  • 研究结束时,MRD阴性CR中10例CR持续,其中9例无MRD。

关键数值与推荐

  • 给药方案:50 µg/kg隔日1次,每周期3次,4周为一周期。
  • MRD阳性CR中位CR持续13.5(4.9-42.4)个月 vs MRD阴性CR 42.1(24.0-69.2)个月(P < .001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anti-CD22 moxetumomab pasudotox achieved 46% complete remissions (CRs) in previously reported phase 1 testing in relapsed/refractory hairy cell leukemia (HCL; n = 28). The importance of minimal residual disease (MRD) after CR in HCL is unknown. A 21-patient extension cohort received 50 µg/kg every other day for 3 doses in 4-week cycles. These patients plus 12 previously reported at this upper dose level received 143 cycles without dose-limiting toxicity. The combined 33-patient cohort achieved 64% CR and 88% overall response rates, with median CR duration of 42.4 months. Of 32 50-µg/kg patients evaluable for MRD by bone marrow aspirate flow cytometry (most stringent assessment), median CR duration was 13.5 (4.9-42.4) months in 9 MRD-positive CRs vs 42.1 (24.0-69.2) months in 11 MRD-negative CRs (P < .001). Among MRD-negative CRs, 10 patients had ongoing CR, 9 without MRD, at end of study. To our knowledge, moxetumomab pasudotox is the only nonchemotherapy regimen that can eliminate MRD in a significant percentage of HCL patients, to enhance CR duration. Repeated dosing, despite early neutralizing antibodies, increased active drug levels without detectable toxicity from immunogenicity. The activity and safety profiles of moxetumomab pasudotox support ongoing phase 3 testing in HCL. This trial was registered at www.clinicaltrials.gov as #NCT00586924.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kreitman RJ, Tallman MS, Robak T, et al. Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. Blood. 2018. PMID: 29487070. doi:10.1182/blood-2017-09-803072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。